Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and ...
– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – PNH is a blood disorder characterized by complement-mediated ...
First and Only Approved Treatment in Japan for Patients Suffering from aHUS, a Chronic and Life-Threatening Ultra-Rare Disease aHUS is a life-threatening and ultra-rare chronic genetic disease that ...
Compare to: Previous Statements by ALXN » Alexion Pharmaceuticals CEO Discusses Q2 2011 Results – Earnings Call Transcript » Alexion Pharmaceuticals Q4 2008 Earnings Call Transcript » Alexion ...
CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for Priority Review ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...
Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at AS
Results from a prospective clinical trial of Soliris in pediatric patients with aHUS, following the published results of a retrospective study in pediatric patients with aHUS Results from an expanded ...
Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...
Only hours after announcing a positive recommendation in Europe for terminal complement inhibitor Soliris (eculizumab) in atypical hemolytic uremic syndrome (aHUS), Alexion Pharmaceuticals Inc. won ...
Alexion's valuation doesn't seem unreasonable relative to the significant sales growth opportunities still in front of the company Soliris, as it is today Soliris is Alexion's complement inhibitor (a ...
Alexion's top-selling drug, Soliris, is getting old, but Alexion still relies on the treatment for 87% of total revenue. The complement inhibitor treats rare blood disorders that include paroxysmal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results